Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of sirukumab in rheumatoid arthritis
NCT01856309Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2013
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of sirukumab in rheumatoid arthritis (RA), sponsored by Janssen Pharmaceutical. Started Aug 2013; status: completed.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01856309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01856309.